Mifepristone
- CAS No.
- 84371-65-3
- Chemical Name:
- Mifepristone
- Synonyms
- RU486;Mifeprestone;Mifepristone INN;C-1073;r38486;ru486-6;VGX 410;MIFEGYNE;RU-38486;Mifeprex
- CBNumber:
- CB6351940
- Molecular Formula:
- C29H35NO2
- Molecular Weight:
- 429.6
- MOL File:
- 84371-65-3.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/5/13 18:00:15
| Melting point | 195-198°C |
|---|---|
| alpha | D20 +138.5° (c = 0.5 in chloroform) |
| Boiling point | 544.13°C (rough estimate) |
| Density | 1.0731 (rough estimate) |
| refractive index | 1.6290 (estimate) |
| storage temp. | 2-8°C |
| solubility | Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 20 mg/ml). |
| form | Yellow solid |
| pka | 12.94±0.60(Predicted) |
| color | Yellow |
| Water Solubility | 474.8ug/L(22.5 ºC) |
| Merck | 14,6186 |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| InChIKey | VKHAHZOOUSRJNA-GCNJZUOMSA-N |
| CAS DataBase Reference | 84371-65-3(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H360 |
| Precautionary statements | P201-P308+P313 |
| Hazard Codes | T |
| Risk Statements | 60-61 |
| Safety Statements | 53-22-36/37/39-45 |
| WGK Germany | 3 |
| RTECS | KG2955000 |
| HS Code | 29372900 |
Mifepristone price More Price(6)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | M8046 | Mifepristone ≥98% | 84371-65-3 | 100MG | ₹11929.15 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M8046 | Mifepristone ≥98% | 84371-65-3 | 500MG | ₹41784.5 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | M8046 | Mifepristone ≥98% | 84371-65-3 | 1G | ₹65285.58 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 475838 | Mifepristone - CAS 84371-65-3 - Calbiochem A cell-permeable synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. | 84371-65-3 | 50MG | ₹10670 | 2022-06-14 | Buy |
| TCI Chemicals (India) | M1732 | Mifepristone | 84371-65-3 | 1G | ₹14000 | 2022-05-26 | Buy |
Mifepristone Chemical Properties,Uses,Production
Description
Mifepristone is an orally-active progesterone and glucocorticoid receptor antagonist indicated for use as a post-coital contraceptive. In addition to being an abortifacient, mifepristone is reported to be effective in the treatment of ocular hypertension; its potential therapeutic effect in hormone-dependent tumors is currently under investigation.
Chemical Properties
Pale Yellow Solid
Uses
Mifepristone is a progesterone receptor antagonist with partial agonist activity. Abortifacient.
Indications
Mifepristone is a progesterone receptor antagonist that has a high affinity for glucocorticoid receptors and little agonist effect.This drug has recently been approved for use in the United States for the treatment of hypercortisolism. At high doses, mifepristone blocks negative feedback of the hypothalamic–pituitary axis, thereby increasing endogenous corticotrophin and cortisol levels. Because mifepristone exerts its effects at the receptor level and not by altering glucocorticoid production, elevated serum cortisol and corticotrophin levels may not accurately reflect the effectiveness of the therapeutic regimen. Mifepristone does not inhibit cortisol binding to the mineralocorticoid receptor, so that the resulting corticotrophin disinhibition may cause potassium depletion. Thus, administration of a mineralocorticoid receptor antagonist such as spironolactone may be indicated with mifepristone. Hypoadrenalism, nausea, and drowsiness have been reported during prolonged administration of mifepristone.
World Health Organization (WHO)
Mifepristone, an antiprogesterone used in combination with a prostaglandin for the termination of early pregnancy, was introduced in 1990. Use of the combination has been associated with episodes of coronary spasm that are attributed to administration of the prostaglandin and which have resulted in several cases of cardiac infarction and ventricular fibrillation. At least one of these incidents has been fatal.
Biological Activity
Selective antagonist at progesterone (PR) and glucocorticoid (GR) receptors in vitro and in vivo . Is a silent antagonist at PR and has a higher affinity than progesterone. Has higher affinity for GR than dexamethasone.
Pharmacokinetics
Following oral administration, mifepristone is rapidly absorbed, with a peak plasmaconcentration in approximately 90 minutes , an oral bioavailability of approximately 70%, and a term inal elimination half-life of 18 hours. It is 98% protein bound, primarily to album in and α1-acid glycoprotein. Mifepristone is metabolized primarily via CYP3A4 pathways involving mono- and di-N-demethylation and terminal hydroxylation of the 17-propynyl chain. The fact that approximately 83% of the drug is recovered in the feces and 9% in the urine suggests a biliary route of elimination. Mifepristone also demonstrates antiglucocorticoid activity.
Clinical Use
An antiprogestin is a substance that competes with progesterone for its receptor and, ultimately, prevents progesterone from binding to and activating its receptor. Because progesterone is integral to the continuation of an early pregnancy, it is expected that antipro-gestins will interfere with pregnancy maintenance. In 1982, the first antiproges tin, mifepristone (RU 486), was reported. Mifepristone was shown to interrupt early stages of implantation and pregnancy in humans.
References
https://pubchem.ncbi.nlm.nih.gov/compound/mifepristone#section=Top
https://www.drugbank.ca/drugs/DB00834
https://www.drugs.com/cdi/mifepristone-tablets.html
Mifepristone Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Gonane Pharma | +91-9819380043 +91-9819380043 | NaviMumbai, India | 192 | 58 | Inquiry |
| Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
| Prachem Laboratories | +91-7948993109 +91-7383072020 | Gujarat, India | 44 | 58 | Inquiry |
| Alfa Omega Pharma | +91-8050045945 +91-9972665399 | Maharashtra, India | 126 | 58 | Inquiry |
| Symbiotec Pharma Lab Pvt Ltd | +91-7316676406 +91-7316676405 | Madhya Pradesh, India | 71 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Biopolis Lifesciences Pvt Ltd | 08047632985 | Haryana, India | 2 | 58 | Inquiry |
| Pellucid Pharma | 08048371509Ext 991 | Ahmedabad, India | 23 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Gonane Pharma | 58 |
| Hetero Drugs Limited | 58 |
| Prachem Laboratories | 58 |
| Alfa Omega Pharma | 58 |
| Symbiotec Pharma Lab Pvt Ltd | 58 |
| CLEARSYNTH LABS LTD. | 58 |
| A.J Chemicals | 58 |
| Pharmaffiliates Analytics and Synthetics P. Ltd | 58 |
| Biopolis Lifesciences Pvt Ltd | 58 |
| Pellucid Pharma | 58 |
84371-65-3(Mifepristone)Related Search:
1of4
chevron_right